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Summary
Objective: In a previous study, we identiﬁed a 50-kDa G3-containing aggrecan degradation product in bovine cartilage, released from the
tissue after interleukin-1 (IL-1) stimulation in the presence of oncostatin M (OSM). Our objective was to purify, determine the N-terminal
sequence of this fragment and verify whether this cleavage could be attributed to a disintegrin and metalloproteinase with thrombospondin
motifs (ADAMTS)-4 and ADAMTS-5 action in vitro.
Methods: Collected media from bovine cartilage explant cultures stimulated with IL-1þOSM were subjected to anion-exchange chromatog-
raphy. The N-terminal sequence of the fragment of interest in the puriﬁed fractions was determined by automated Edman sequencing. Fetal
bovine aggrecan was digested with full-length recombinant ADAMTS-4 and ADAMTS-5 and resulting degradation products were analyzed by
sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS/PAGE) and immunoblotting using an anti-G3 antiserum and an anti-
neoepitope antibody that had been generated to the new N-terminus of the G3 fragment.
Results: Characterization of the 50-kDa fragment showed that it possesses chondroitin sulfate (CS) and is the result of a cleavage within the
C-terminal portion of the CS-2 domain, adjacent to the G3 region. Sequence analysis identiﬁed the cleavage region as TQRPAE2047e2048-
ARLEIE, suggesting an aggrecanase-derived product. Using an anti-neoepitope antibody speciﬁc for the additional cleavage site, it was
shown that the product is generated in vitro upon digestion of aggrecan by ADAMTS-5 and, to a much lesser extent, by ADAMTS-4.
Conclusions: The abundance and rapid rate of release of this degradation product in organ cultures in the presence of OSM suggest that it
could result from a unique aggrecan proteolysis mediated by aggrecanases.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Aggrecan is the most abundant proteoglycan in the extra-
cellular matrix (ECM) of articular cartilage, where it is bound
non-covalently to a hyaluronan (HA) ﬁlament forming large,
negatively charged macromolecular proteoglycan aggre-
gates that are responsible for the hydration of the cartilage
and therefore the capacity of the tissue to withstand the
deformation and compressive forces to which it is exposed.
Aggrecan consists of a 250-kDa core protein composed of
three globular domains (G1, G2 and G3) and an extended
region consisting of three sub-domains, which are heavily
substituted with keratan sulfate (KS) and chondroitin sulfate
(CS) glycosaminoglycan (GAG) side chains (Fig. 1, panel
A)1,2. At the N-terminus, the G1 domain is responsible for
the non-covalent binding of aggrecan to HA3, an interaction
that is further stabilized by a small glycoprotein termed the
link protein (LP) which binds to both the G1 domain and HA.
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1245residue interglobular domain (IGD), shares structural ho-
mology with the G1-HA binding region, but lacks the ability
to bind to HA3,4. The G3 domain is located at the C-termi-
nus of the molecule and is structurally different from both
G1 and G2 domains. The extended region between the
G2 and G3 domains is substituted by KS (KS-rich domain)
and a very large number of CS (CS-1 and CS-2 domains)
side chains.
Depletion of aggrecan from cartilage is a key-event in
many arthritic diseases. This is the result of proteolytic cleav-
age along the aggrecan core protein by proteases that are
present within the joint. Matrix metalloproteinases (MMPs),
such as MMP-1, MMP-3, MMP-8 and MMP-135e9, as well
as aggrecanases, members of a disintegrin and metallopro-
teinase with thrombospondin motifs (ADAMTS) family, such
as ADAMTS-1, ADAMTS-4 and ADAMTS-510e12, have been
shown to cleave aggrecan at sites within the IGD that are
speciﬁc for each enzyme family. Cleavage at these sites re-
sults in the loss of aggrecan fragments bearing the GAG side
chains and therefore the loss of the osmotic properties of the
tissue. Among these enzymes, ADAMTS-4 and ADAMTS-5
are considered to be the most likely candidates for aggrecan
degradation under arthritic conditions, as they have been
shown to be expressed in arthritic cartilage, to be localized
in areas of aggrecan depletion, and to have the highest
aggrecanolytic activities in vitro. Four ADAMTS-4 and
Fig. 1. Aggrecanase cleavage sites in bovine aggrecan. (A) Schematic representation of the bovine aggrecan core protein and its constituent
domains: G1, IGD, G2 and G3, and the GAG-substituted domains: KS and CS-1 and CS-2 domains. Previously described aggrecanase cleav-
age sites are indicated by numbered arrows (1e5). Position of the additional aggrecanase-mediated cleavage site described in the present
work is indicated by the dashed arrow (6). (B) Sites cleaved by aggrecanases. Cleavage site is indicated by an arrow and the position of the
P1 glutamic acid residue in the bovine aggrecan sequence is also indicated.
1246 M. Durigova et al.: OSM-mediated aggrecan degradationADAMTS-5-mediated cleavage sites have also been de-
scribed within the CS-2 region of aggrecan13,14, generating
small G3-containing fragments whose size is the hallmark
of aggrecanase action (Fig. 1, panel A). The aggrecanase-
mediated cleavage sites all have Glu at the P1 position
and a non-polar or uncharged residue such as Gly, Ala or
Leu at the P10 position. In bovine cartilage these cleavages
are AGELE1480e1481GRGTI, FKEE1666e1667GLGSV,
PTAQE1771e1772AGEGP, TVSQE1871e1872LGQRP
(Fig. 1, panel B)15 and, along with the cleavage site within
the IGD, are highly conserved between various species16.
Under arthritic conditions proinﬂammatory cytokines such
as interleukin-1 (IL-1), tumor necrosis factor-a (TNF-a) and
oncostatin M (OSM) are known to stimulate the production
and activation of aggrecanases17e20, and are therefore re-
sponsible for the rapid degradation of aggrecan under these
conditions. We have previously studied the effects of
combinations of these catabolic cytokines on proteoglycan
aggregate degradation in adult bovine articular cartilage21.
Western blot analysis of deglycosylated culture media using
an antibody directed against the C-terminal G3 domain of
aggrecan has revealed the presence of an additional degra-
dation product with an apparent molecular mass of
w50 kDa that was generated in the presence of OSM,
either alone or in combination with the other cytokines. In
this study we have puriﬁed the 50-kDa fragment from cyto-
kine-stimulated bovine cartilage culture medium, identiﬁed
the cleavage site within the aggrecan core protein, and
determined that this G3-containing fragment is the product
of ADAMTS action in vitro.MethodsBOVINE CARTILAGE EXPLANT CULTURESBovine articular cartilage was obtained at a local abattoir from skeletally
mature animals. Cartilage from metacarpophalangeal joints was cut into
pieces (approximately 5 mm3); pre-cultured at 37C in 5% CO2 in Dulbecco’s
modiﬁed Eagle medium (DMEM) buffered with 44-mM NaHCO3, 20-mM
HEPES, and containing 100-U/ml penicillin G sodium and 100-mg/ml strepto-
mycin sulfate (Gibco), in 12-well culture plates at 100-mg tissue per 2-ml
medium. The explants were then cultured for 4 days in DMEM containing0.1-mg/ml BSA as a carrier and supplemented with a combination of human
recombinant IL-1b (5 ng/ml) and OSM (10 ng/ml) (R&D)21. Media were
collected at day 2 and day 4 of the culture.KERATANASE AND CHONDROITINASE TREATMENTSAliquots of the conditioned culture medium were dialyzed against 10-mM
sodium acetate, pH 6.0 (keratanase buffer) at 4C and treated with 20-mU/ml
keratanase II (Seikagaku) at 37C overnight. Subsequently, the buffer was
adjusted to 0.1-M Tris/HCl, 0.1-M sodium acetate, pH 7.3 and the samples
were treated with 200-mU/ml chondroitinase ABC (MP Biomedicals) for 6 h
at 37C. At the end of the digestion period both enzymes were inactivated
by incubation of the samples at 100C for 5 min.WESTERN BLOTKeratanase/chondroitinase-treated samples were analyzed on Novex
4e12% gradient NuPAGE BiseTris gels (Invitrogen) under reducing condi-
tions. Electrophoresis was performed at 180 V for 1 h 30 min and electro-
blotting to nitrocellulose membrane (Bio-Rad) was conducted for 2 h at 30 V.
The membrane was blocked overnight in 5% skim milk (Carnation Instant
milk powder) in Tris-buffered saline, pH 7.6 containing 0.1% Tween 20. Aggre-
can degradation products were detected using rabbit polyclonal antibodies
(1:1000), recognizing the G3 domain of aggrecan22 or the new N-terminus
(ARLEIE) of the G3-bearing aggrecan fragment described below. Binding of
the primary antibodywas detectedusing a secondary anti-rabbit Ig-biotinylated
antibody (Amersham), followed by incubation with a streptavidin-biotinylated
horseradish peroxidase (HRP) complex (Amersham), ECL Plus Western blot-
ting detection reagents (Amersham), and exposure to Hyperﬁlm (Amersham).FRAGMENT PURIFICATION BY ION-EXCHANGE
CHROMATOGRAPHYIL-1/OSM-treated cartilage culture media were pooled and subjected to
DEAE Sepharose Fast Flow (Amersham) anion-exchange chromatography
to purify aggrecan fragments. The sample was applied on a DEAE-Sephar-
ose column (5 ml) equilibrated in 50-mM Tris, 0.15-M NaCl, pH 7.5. Fractions
of 1 ml were collected at a ﬂow rate of 20 ml/h. Bound aggrecan fragments
were retrieved by step elution in 50-mM Tris, pH 7.5, containing 0.3-M and
1-M NaCl (10 ml). The protein content of the collected fractions was moni-
tored by measuring absorbance at 280 nm. Aggrecan G3-containing frag-
ments were identiﬁed by SDS/PAGE and immunoblotting (as described
above). Fractions containing the 50-kDa G3-containing aggrecan fragment
were then extensively dialyzed into 10-mM sodium acetate, pH 6.0 to reduce
the NaCl concentration in the sample. The proteins were precipitated with
four volumes of ethanol and the pellet was resuspended in a small volume
of keratanase buffer for subsequent keratanase and chondroitinase treat-
ments and western blot analysis as described above.
1247Osteoarthritis and Cartilage Vol. 16, No. 10N-TERMINAL SEQUENCE DETERMINATIONFractions containing the 50-kDa G3-containing aggrecan degradation
product were subjected to SDS/PAGE using 4e12% Novex gels (Invitrogen)
and the products transferred to polyvinylidene diﬂuoride (PVDF) membrane
(Bio-Rad) by electroblotting as described above. The membrane was stained
with 0.1% Coomassie Blue R-250 in 50% methanol, then brieﬂy destained in
50% methanol and washed with water. Bands corresponding to the degrada-
tion product of interest were excised and analyzed by automated Edman
degradation sequencing (carried out at the Sheldon Biotechnology Centre,
McGill University).GENERATION OF ANTI-NEOEPITOPE ANTIBODIESAn anti-neoepitope antibody to the new N-terminus of the 50-kDa G3-
containing aggrecan fragment was generated as described previously23
by immunization of a rabbit (carried out at the McGill University Animal
Resource Centre) with a synthetic peptide, ARLEIEGGC, coupled to
keyhole-limpet haemocyanin (KLH). The residues indicated in italics repre-
sent a linker region, consisting of a cysteine residue, to permit the conjuga-
tion to KLH, and two glycine spacer residues. The resulting antiserum was
assayed for selectivity by competitive enzyme-linked immunosorbant assay
(ELISA), as described previously23, using the immunizing peptide as well
as a test-peptide that differs from the immunizing peptide by a substitution
of the ﬁrst two N-terminal residues (AR/ TH). The speciﬁcity of the anti-
neoepitope antibody was also veriﬁed in immunoblotting experiments
against intact aggrecan.Fig. 2. Release of G3-containing fragments from bovine cartilage
explant cultures. Bovine cartilage explants were cultured in the
presence of IL-1b and OSM over a 4-day period. Culture mediumEXTRACTION OF FETAL BOVINE AGGRECANwas collected at day 2 and day 4, treated with keratanase II and
chondroitinase ABC, analyzed by SDS/PAGE and immunoblotting
using an antibody recognizing the G3 domain of aggrecan. Material
released from equal amounts of cartilage explants was loaded
onto the gel. Lane 1, control day 2; lane 2, IL-1bþOSM day 2;
lane 3, IL-1bþOSM day 4. Migration positions of molecular weight
markers are indicated on the left. Migration position of the additional
G3-bearing fragment is indicated by an arrow.Fetal bovine cartilage from the epiphyses of metacarpal bones was
obtained from a local abattoir. Proteoglycan was extracted with 4-M guanidi-
nium chloride as described previously24. Filtered extracts were adjusted to
a density of 1.5 g/ml by addition of cesium chloride, while the concentration
of guanidinium chloride was maintained at 4 M. The extract was then sub-
jected to density-gradient centrifugation at 100,000 gav at 10
C for 48 h.
Fractions of density >1.55 g/ml were pooled, desalted by dialysis, freeze-
dried and stored at 4C until subsequent use for aggrecanase digestion.DIGESTION OF BOVINE AGGRECAN WITH RECOMBINANT
ADAMTS-4 AND ADAMTS-5Recombinant full-length aggrecanases were expressed in insect cells and
puriﬁed as described previously and the concentrations of active ADAMTS-4
and ADAMTS-5 determined by titration with the N-terminal domain of tissue in-
hibitor of metalloproteinases-3 (TIMP3)25,26. All aggrecan digestion assays
were carried out in 100-ml 50-mM TriseHCl buffer, pH 7.5, containing 125-
mM NaCl and 5-mM CaCl2 (aggrecanase buffer) containing 200 mg of puriﬁed
fetal bovine aggrecan. The samples were incubated with ADAMTS-4 or
ADAMTS-5 at 5 nM for 24 h at 37C and the reaction was stopped by heating
the samples at 75C for 10 min. In addition, a time-course study of ADAMTS-
5 digestion was carried out using 1 nM of the enzyme, with digestion being
stopped after 1, 3, 6 and 18 h. For analysis, samples were then precipitated
by adding four volumes of cold ethanol, incubated overnight at 20C and
centrifuged. The pellet was washed with cold ethanol, dried and resuspended
in keratanase buffer for subsequent keratanase and chondroitinase treatments
and western blot analysis, as described above.ResultsRELEASE OF G3-CONTAINING FRAGMENTS
INTO CULTURE MEDIUMCulture media of bovine cartilage explants treated with IL-
1b in combination with OSM over a 4-day culture period
were analyzed by SDS/PAGE and immunoblotting. After 2
days of culture in the absence of cytokines, intact high mo-
lecular weight aggrecan was detected in the culture media,
with very little sign of proteolytic degradation (Fig. 2, lane 1).
No further degradation was observed after 4 days of culture.
However, in the presence of IL-1b and OSM, several degra-
dation products could be detected (Fig. 2, lanes 2 and 3).
The sizes of the larger fragments are compatible with ag-
grecanase cleavage within the CS-2 region of aggrecan.
An additional 50-kDa fragment was also detected. Its size
and detection by the anti-G3 antibody suggest that it could
consist of a ‘‘free’’ G3 domain.PURIFICATION OF G3-CONTAINING FRAGMENTS
BY ION-EXCHANGE CHROMATOGRAPHYG3-containing fragments were puriﬁed by anion-
exchange chromatography from 76 ml of pooled culture
medium from bovine explants treated with IL-1b and
OSM. Aggrecan fragments containing the G3 domain, in-
cluding the 50-kDa fragment, remained bound to the col-
umn and were eluted with increasing NaCl concentrations
(Fig. 3, panels A and B), indicating their anionic character
and the presence of GAG chains. In addition, a 30-kDa
G3-containing product was also detected (Fig. 3, panel
B), although in lower abundance than the 50-kDa fragment.AMINO ACID SEQUENCE ANALYSIS OF G3-CONTAINING
FRAGMENTTo establish the N-terminal amino acid sequence of the
50 kDa fragment, fraction 98 (Fig. 3, panel B) was fraction-
ated by SDS/PAGE, transferred to PVDF membrane, and
identiﬁed with Coomassie blue (Fig. 4). The 50-kDa band
was excised and subjected to protein sequencing. A single
sequence was obtained: ARLEIESSSP, which corresponds
to residues 2047e2056 in the published protein sequence of
bovine aggrecan (accession number: NP_776406). This in-
dicated that cleavage has occurred within the CS-2 region of
aggrecan between Glu2047 and Ala2048. The amino acid se-
quence surrounding the cleavage site is TQRPAEeARLEIE.
This could be a putative cleavage site for aggrecanases,
which are considered to be glutamyl-endopeptidases13.DIGESTION OF AGGRECAN WITH AGGRECANASESTo verify that such a cleavage can be reproduced in vitro
by aggrecanases, fetal bovine aggrecan was digested by
Fig. 3. Puriﬁcation of G3-containing aggrecan fragments by ion-
exchange chromatography. (A) Culture media from day 2 and day
4 of IL-1b/OSM-treated explant cultures were pooled and loaded
onto a DEAE-Sepharose column pre-equilibrated in 50-mM Tris,
0.15-M NaCl, pH 7.5. Bound aggrecan material was retrieved by
step elution with 0.3-M and 1-M NaCl. Protein content in the
collected 1-ml fractions was estimated by measuring absorbance
at 280 nm. (B) Aliquots of the fractions were deglycosylated and
analyzed by SDS/PAGE and western blotting using anti-G3 anti-
body. Migration positions of molecular weight markers are indicated
on the left. Migration position of the G3-bearing fragment of interest
is indicated by an arrow.
Fig. 4. Amino acid sequence analysis of G3-containing aggrecan
fragment. Fraction number 98 [see Fig. 3(B)] containing the G3
product of interest was treated with keratanase II and chondroiti-
nase ABC. The sample was run on a 4e12% BiseTris Novex
gels and transferred to a PVDF membrane. The Coomassie Blue-
stained band of interest (marked by an arrow) was excised and
analyzed by automated Edman degradation sequencing. The
determined N-terminal sequence is indicated.
Fig. 5. Digestion of fetal bovine aggrecan with aggrecanases. Puri-
ﬁed fetal bovine aggrecan (2 mg/ml) was digested with recombinant
full-length human ADAMTS-4 or ADAMTS-5 (5 nM) for 24 h at
37C. The samples were then treated with keratanase II and chon-
droitinase ABC, then analyzed by SDS/PAGE and immunoblotting
using either an anti-aggrecan G3 antibody (A) or an anti-neoepitope
antibody directed against the new N-terminus of the G3 fragment
(B). Lane 1, undigested aggrecan; lane 2, aggrecan digested with
ADAMTS-4; lane 3, aggrecan digested with ADAMTS-5; lane 4, cul-
ture media from IL-1b/OSM-treated bovine explants collected at
day 4. Migration positions of molecular weight markers are indi-
cated on the left. Migration position of the G3-bearing fragment of
interest is indicated by an arrow.
1248 M. Durigova et al.: OSM-mediated aggrecan degradationrecombinant full-length ADAMTS-4 and ADAMTS-5, and
G3-containing fragments were analyzed by immunoblotting.
Fetal bovine aggrecan was used as a substrate because of
its high content of intact aggrecan molecules bearing the
G3 domains. Treatment with ADAMTS-4 (Fig. 5, panel A,
lane 2) or ADAMTS-5 (Fig. 5, panel A, lane 3) resulted in
the generation of several G3-containing products that
were absent in the undigested aggrecan (Fig. 5, panel A,
lane 1). The sizes of these degradation products were com-
patible with aggrecanase-mediated cleavages within the
CS-2 region of aggrecan. ADAMTS-4 generated two prod-
ucts that have been previously shown to be due to cleav-
ages at Glu1771eAla1772 and Glu1871eLeu1872. ADAMTS-5
also generated these degradation products, with cleavage
at Glu1871eLeu1872 being predominant. Both aggrecanases
were also able to generate the 50-kDa G3-containing frag-
ment, though in vastly different abundance. ADAMTS-5
readily cleaves at this site, whereas cleavage by ADAMTS-4
could only be detected when excessive amounts of digest
were used (data not shown). Medium from day 4 of bovineexplant cultures stimulated with IL-1b and OSM (Fig. 5,
panel A, lane 4), exhibits an equivalent aggrecan degrada-
tion pattern to that of fetal bovine aggrecan digested with
ADAMTS-5.
1249Osteoarthritis and Cartilage Vol. 16, No. 10In order to verify that the 50-kDa G3-containing aggrecan
fragment was the product of aggrecanase activity at
Glu2047eAla2048, immunoblotting was repeated using an
anti-neoepitope antibody recognizing the new N-terminal
amino acid sequence of the 50-kDa fragment, ARLEIE.
The ARLEIE epitope was not detected in undigested aggre-
can (Fig. 5, panel B, lane 1). However, upon digestion by
ADAMTS-5, abundant ARLEIE-G3 product was detected
(Fig. 5, panel B, lane 3). In contrast, a large amount of
ADAMTS-4-digested material was necessary to detect the
50-kDa ARLEIE-G3 product with the anti-neoepitope anti-
body (data not shown). This conﬁrms that full-length
ADAMTS-5 is more active than ADAMTS-4 at cleaving
the Glu2047eAla2048 bond. As expected, the 50-kDa frag-
ment was also detected by the anti-neoepitope antibody
in the culture media of IL-1b and OSM-treated adult bovine
cartilage explants (Fig. 5, panel B, lane 4).
To determine whether the cleavage at the Glu2047eAla2048
bond represents a preferential or a terminal cleavage, a time-
course study of digestion of fetal bovine aggrecan by
ADAMTS-5 was performed (Fig. 6). G3-bearing degradation
products resulting from the cleavages within the CS-2
region of aggrecan were detected after 1 h of digestion
(Fig. 6, lane 2). These degradation products accumulate
over time, with cleavage following Glu1871 being predomi-
nant after 1, 3 and 6 h of digestion (Fig. 6, lanes 2e4).
However, as the 1872Leu-G3 fragments accumulate, they
are progressively converted into the described 50-kDa
G3-containing products (Fig. 6, lanes 3e4), and after 18 h
of digestion the 50-kDa fragment is the major degradation
product (Fig. 6, lane 5). Thus, the 2048Ala-G3 fragment rep-
resents a terminal cleavage product of aggrecan by
ADAMTS-5.Fig. 6. Digestion of fetal bovine aggrecan by ADAMTS-5: a time-
course study. Puriﬁed aggrecan (2 mg/ml) was digested with
recombinant human ADAMTS-5 (1 nM) for 1, 3, 6 or 18 h at
37C. The samples were then treated with keratanase II and chon-
droitinase ABC, and analyzed by SDS/PAGE and immunoblotting
using an anti-aggrecan G3 antibody. Lane 1, undigested aggrecan;
lane 2, aggrecan digested with ADAMTS-5 for 1 h; lane 3, aggrecan
digested with ADAMTS-5 for 3 h; lane 4, aggrecan digested with
ADAMTS-5 for 6 h; lane 5, aggrecan digested with ADAMTS-5 for
18 h. Migration positions of molecular weight markers are indicated
on the left. Migration position of the G3-bearing fragment of interest
is indicated by an arrow.ANALYSIS OF CS AND KS PRESENCE OF G3-CONTAINING
FRAGMENTThe ability of the 50-kDa fragment to bind to the DEAE
resin suggests that it is substituted with GAG chains. The
presence of such GAG chains was conﬁrmed by treating
the fetal bovine aggrecan ADAMTS-5 digests with either
chondroitinase ABC and/or keratanase II; followed by
SDS/PAGE and immunoblotting (Fig. 7). Non-deglycosy-
lated samples, whether they were treated with or without
ADAMTS-5, could not be detected by the anti-G3 or anti-
ARLEIE antibody (Fig. 7, panels A and B, lanes 1 and 2).
Similarly, keratanase treatment alone of the ADAMTS-5-di-
gested aggrecan did not allow the detection of aggrecan
degradation products by either antibody (Fig. 7, panels A
and B, lane 3). In contrast, treatment with chondroitinase
(Fig. 7, panel A, lanes 4 and 5) allowed the detection of
115-kDa and 50-kDa fragments by the anti-G3 antibody
and the 50-kDa fragment by the anti-ARLEIE antibody
(Fig. 7, panel B, lanes 4 and 5). This indicates that the
50-kDa G3 fragment contains at least one CS chain. A sim-
ilar experiment using chondroitinase and/or keratanase
treatment of culture media collected from IL-1/OSM-treated
bovine cartilage explants veriﬁed that chondroitinase treat-
ment is essential to visualize the 50-kDa G3-bearing frag-
ment by immunoblotting (data not shown).Discussion
The results presented in this and a previous study21,
have shown that OSM in combination with IL-1b, is capable
of stimulating bovine aggrecan degradation not only at the
previously described aggrecanase-sensitive cleavage sites
within the IGD and CS-2 domains of aggrecan, but also at
an additional site within the CS-2 region. This was a terminal
cleavage, and resulted in the release of a 50-kDa G3-
bearing fragment. Analysis indicates that the fragment isFig. 7. Analysis of CS and KS presence of G3-containing aggrecan
fragment. ADAMTS-5 digests of fetal bovine aggrecan were treated
with either keratanase II or chondroitinase ABC, or both enzymes.
Sample were then analyzed by SDS/PAGE on 4e12% BiseTris
Novex gels and immunoblotting using either an anti-aggrecan G3
antibody or an anti-neoepitope antibody directed against the new
N-terminus of the G3 fragment. Migration positions of molecular
weight markers are indicated on the left. Migration position of the
G3-bearing fragment of interest is indicated by an arrow.
Fig. 8. Sequence comparison between different species at the C-
terminal aggrecanase cleavage site. Bovine, human, dog, mouse
and rat aggrecan amino acid sequences at the cleavage site
were aligned. P1 indicates the ﬁrst amino acid upstream of the
scissile bond; P10 represents the ﬁrst amino acid downstream of
the scissile bond. Amino acids are represented by their respective
single letter code.
1250 M. Durigova et al.: OSM-mediated aggrecan degradationgenerated by cleavage near the C-terminus of the CS-2
domain, and that it possesses at least one CS chain.
In addition to the predominant 50-kDa G3 fragment,
a minor 30-kDa fragment was also detected. Neoepitope
analysis indicates that the 30-kDa fragment possesses
the same N-terminal amino acid sequence as the 50-kDa
fragment (unpublished data). Although this fragment is not
produced by ADAMTS-4 or ADAMTS-5 treatment of fetal
bovine cartilage aggrecan, additional studies have shown
that ADAMTS-5 can generate such a fragment from adult
bovine aggrecan (unpublished data). Thus, the 30-kDa is
probably derived from the C-terminally processed aggrecan
that may be present in mature cartilage.
In the bovine aggrecan gene, the CS-2 domain of aggre-
can is encoded by exon 12, whereas the downstream exons
code for the various sub-domains of the G3 domain27. The
N-terminal sequence of the 50-kDa G3 fragment veriﬁed
that the cleavage site is located within the region encoded
by exon 12, close to the C-terminus of the CS-2 domain
of aggrecan (Fig. 1). Further analysis of the bovine aggre-
can sequence shows that a potential sequence for CS chain
substitution (2060SereGly) is present within the 50-kDa frag-
ment, so accounting for its anionic character and sensitivity
to chondroitinase.
Generation of an aggrecan fragment with the same N-
terminal amino acid sequence as the 50-kDa fragment
has been previously reported from the culture media of
bovine ligament explants28. It seems that in the ligament
this fragment is a naturally occurring catabolite of aggrecan
as no cytokine stimulation was necessary for the fragment
to be released from the tissue. An aggrecan fragment of
similar size has also been previously observed and re-
ported as an m-calpain generated product29, and evidence
has been presented for the role of this protease in cartilage
degradation30. However, in cartilage, aggrecan turnover,
both under normal and pathological conditions, is thought
to be mediated mainly by aggrecanases (ADAMTS-4 and
ADAMTS-5), as products derived from cleavages by these
enzymes can be detected in synovial ﬂuids of patients suf-
fering from OA, joint injury or inﬂammatory joint diseases31.
The 50-kDa G3 fragment described in this study is gener-
ated by cleavage following a glutamic acid residue. Such
cleavage is not characteristic of m-calpain action, but rather
implicates aggrecanases. It was suggested that aggreca-
nase action accounted for generation of the G3 fragment
from the cultured bovine ligament28, though there was no di-
rect evidence to support this proposal. Use of an anti-neo-
epitope antibody speciﬁc to the N-terminus of the 50-kDa
G3 fragment conﬁrms that the observed cleavage can be
mediated by both ADAMTS-4 and ADAMTS-5 in vitro. How-
ever, these enzymes do not cleave this region to the same
extent, with full-length recombinant ADAMTS-5 cleaving
much more readily than ADAMTS-4. This is not surprising
as previous studies have shown that recombinant full-length
ADAMTS-4 and ADAMTS-5 used in these studies exhibit
different levels of activity, with ADAMTS-5 being up to
20e30 times more efﬁcient at cleaving aggrecan than
ADAMTS-426,32.
Variations in the activity of the aggrecanases in cleaving
aggrecan have been previously reported. These enzymes
have variable activities within the different cleavage regions
of the aggrecan core protein and while cleavage at the
Glu373eAla374 site within the IGD is considered to be the
signature of aggrecanase activity, it has been shown that
cleavage within the CS-2 region is more favored33e35.
Moreover, the presence of CS chains has been described
as an important feature in promoting aggrecanase activity,as both ADAMTS-4 and ADAMTS-5 have been shown to
interact with GAG side chains through their ancillary C-
terminal domains36,37. Furthermore, the activities of both
ADAMTS-4 and ADAMTS-5 can be regulated by C-terminal
processing, either by autocatalysis or the action of other
proteases38,39. Previous studies have suggested the pres-
ence of truncated forms of ADAMTS-4 lacking the spacer
domain or part of the Cys-rich domain in pig cartilage follow-
ing IL-1 treatment38,40. Such truncated forms of ADAMTS-4
exhibit lower aggrecanase activities in the CS-2 region25.
Similarly, truncated forms of ADAMTS-5 have been de-
tected in human synovial tissue41, and studies have shown
that ADAMTS-5 lacking the spacer domain exhibits reduced
aggrecanase activities in both the IGD and the CS-2
regions26.
The presence of the 50-kDa aggrecan fragment in OSM-
treated bovine cartilage suggests that cleavage at
Glu2047eAla2048 could occur in vivo during cartilage catab-
olism, when OSM is present within the joint. OSM is a cyto-
kine associated with mononuclear cells and is believed to
play an important role in the degradation of the main ECM
components, aggrecan and collagen type II, in the inﬂam-
matory joint42e44. Interestingly, bovine chondrocytes
treated with IL-1 express both OSM and OSM receptor
mRNA (unpublished data), suggesting that bovine chondro-
cytes could produce this cytokine as well as readily respond
to its presence within the joint. Our previous data suggest
that OSM might play a role in enhancing the effect of other
catabolic cytokines such as IL-1 and TNF-a, resulting in ex-
cessive disruption of the ECM scaffold through degradation
of HA in addition to enhanced aggrecanolysis21. Previous
studies have shown that OSM alone is capable of inducing
ADAMTS-4 and MMP-13 expressions by human articular
chondrocytes45. Furthermore, in combination with TNF-a,
OSM has been shown to stimulate ADAMTS-5 mRNA
expression in bovine nasal and human articular chondro-
cytes46. High levels of aggrecanase production induced
by OSM could therefore account for the observed extensive
aggrecan degradation characterized in this study. Prelimi-
nary studies involving PCR analysis of bovine cartilage
explants treated with IL-1þOSM or IL-1 alone over a 2-
or 4-day culture period have indicated that ADAMTS-5
mRNA levels are elevated when OSM is present, support-
ing a potential role for ADAMTS-5 in the generation of the
50-kDa aggrecan product (unpublished observations). In
addition, it is possible that OSM inﬂuences aggrecanase
C-terminal truncation, so altering the afﬁnity of the different
forms of the enzymes for the aggrecan.
The four well characterized aggrecanase cleavage sites
located within the CS-2 region of aggrecan are very well
conserved among species. However, the additional C-
terminal cleavage site reported in this study shows variation
between the species (Fig. 8). The N-terminal region of the
1251Osteoarthritis and Cartilage Vol. 16, No. 10scissile bond is fairly well conserved between the species,
with the glutamic acid residue at the P1 position being
100% conserved. Recent studies have described a seven
amino acid putative cleavage motif for ADAMTS-4 action
in aggrecan47, and it has been suggested that an extended
region downstream of the scissile bond (P0 amino acids) is
involved in substrate recognition47,48. Such downstream se-
quence exhibits the most variation between species (Fig. 8).
In addition, the presence of CS-attachment motifs in the
proximity of the cleavage site could also have an impact
on aggrecanases action. Sequence comparison revealed
that the potential CS-substitution motifs, located upstream
and downstream of the C-terminal cleavage site, are well
conserved between the species (data not shown) and could
therefore facilitate aggrecanase action. However, whether
the presence of sequence variations impairs or enhances
aggrecanase action in these species still needs to be
established.Conﬂict of interest
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